Galera Therapeutics Inc.
0.05
0.00 (5.26%)
At close: Jan 15, 2025, 3:30 PM
0.05
0.87%
Pre-market Jan 10, 2025, 09:30 AM EST

Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.

The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy.

It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer.

The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Galera Therapeutics Inc.
Galera Therapeutics Inc. logo
Country United States
IPO Date Nov 7, 2019
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Dr. J. Mel Sorensen M.D.

Contact Details

Address:
2 West Liberty Boulevard
Malvern, Pennsylvania
United States
Website https://www.galeratx.com

Stock Details

Ticker Symbol GRTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001563577
CUSIP Number 36338D108
ISIN Number US36338D1081
Employer ID 46-1454898
SIC Code 2834

Key Executives

Name Position
Dr. J. Mel Sorensen M.D. Chief Executive Officer, President & Director

Latest SEC Filings

Date Type Title
Jan 14, 2025 D Filing
Jan 13, 2025 D Filing
Jan 02, 2025 4 Filing
Jan 02, 2025 3 Filing
Jan 02, 2025 4 Filing
Jan 02, 2025 3 Filing
Dec 31, 2024 8-K Current Report
Dec 20, 2024 8-K Current Report
Dec 13, 2024 10-Q Quarterly Report
Nov 15, 2024 NT 10-Q Filing